Genetic characterization drives personalized therapy for early-stage non-small-cell lung cancer (NSCLC) patients and survivors with metachronous second primary tumor (MST): A case report

RATIONALE: The pathogenesis and progression of lung cancer is a complicated process in which many genes take part. But molecular gene testing is typically only performed in advanced-stage non-squamous non-small-cell lung cancer (NSCLC). The value of tyrosine kinase inhibitors (TKI) administration is...

Descripción completa

Detalles Bibliográficos
Autores principales: Ding, Xingchen, Wang, Linlin, Liu, Xijun, Sun, Xindong, Yu, Jinming, Meng, Xue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5348162/
https://www.ncbi.nlm.nih.gov/pubmed/28272214
http://dx.doi.org/10.1097/MD.0000000000006221

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5348162/
https://www.ncbi.nlm.nih.gov/pubmed/28272214
http://dx.doi.org/10.1097/MD.0000000000006221

Ejemplares similares